Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Selexis SA Stories

2014-03-26 23:24:54

Dr. Pierre-Allain Girod to Present on Data on Engineering CHO Cell Lines for Enhanced Production of Monoclonal Antibodies and Fc:Fusion Proteins Geneva, Switzerland (PRWEB) March 26, 2014 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s chief scientific officer, Pierre-Allain Girod, Ph.D., will present, “Selexis SURE CHO-Mplus™...

2014-02-27 23:27:06

Selexis CSO Demonstrates How the Selexis SURE CHO-Mplus™ Libraries Can Dramatically Improve Biologic Protein Expression in Mammalian Cell Lines Geneva, Switzerland (PRWEB) February 27, 2014 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today it will host a free webinar to educate scientists and researchers about the SURE CHO-Mplus™ Libraries to...

2014-02-25 23:26:17

Selexis to Meet with Biopharmaceutical Companies Interested in Protein Drug Discovery, Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing Geneva, Switzerland (PRWEB) February 25, 2014 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the...

2014-01-13 16:26:26

GENEVA, Jan. 13, 2014 /PRNewswire/ -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs announced today that Opthea Pty Ltd has entered into a commercial license agreement with Selexis covering the use of the CHO-M Cell Line and related technologies for the production of OPT-302 (formerly VGX-300), an Fc fusion protein for the treatment of wet Age-Related...

2013-12-17 23:04:19

CSO to Present Data on the Recently Launched SURE CHO-Mplus™ Libraries Geneva, Switzerland (PRWEB) December 17, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs announced today data from the Company’s SURE CHO-Mplus™ Libraries will be presented at the 13th Annual PepTalk Conference, January 13-17, 2014 at the Renaissance Hotel & Palm Springs...

2013-12-03 12:25:52

Strategic Alliance to Provide Seamless Services from Cell Line Development to cGMP Manufacturing of Biologic Drugs HSINCHU, Taiwan and GENEVA, Dec. 3, 2013 /PRNewswire/ -- JHL Biotech, Inc., a provider of biopharmaceutical process development and manufacturing services, and Switzerland-based Selexis SA, a provider of technologies for mammalian cell line development, announced today that they have signed a non-exclusive strategic agreement to provide biopharmaceutical customers a seamless...

2013-11-19 23:20:50

Former Quintile executive brings more than 15 years of life science and regulatory knowledge to Selexis Geneva, Switzerland (PRWEB) November 19, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the hire of Marco Bocci, PhD, DPharm, as Director of European Sales and Business Development. Dr. Bocci joins Selexis from Quintiles and will be...

2013-10-24 23:21:55

Dr. Igor Fisch to Present Data on Using the SURE CHO-Mplus Combinatorial Library to Address a Broad Range of Protein Production Bottlenecks Geneva, Switzerland (PRWEB) October 24, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s president and CEO, Igor Fish, Ph.D., will present, “Selexis SURE CHO-Mplus™ Libraries: Custom...

2013-07-31 23:26:04

CSO to Present Data on Using the SURE CHO-Mplus Combinatorial Library to Address a Broad Range of Protein Production Bottlenecks Geneva, Switzerland (PRWEB) July 31, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company will present data on the SURE CHO-Mplus™ Library at the Bioprocessing Summit being held August 19 – 23 at the...

2013-07-16 23:04:49

Selexis to Meet with Companies Interested in Protein Drug Discovery, Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing Geneva, Switzerland (PRWEB) July 16, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the BIO Taiwan 2013...